Participant flow

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia · Source last updated 2026-08-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4. TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure. clofarabine: Given IV melphalan: Given IV allogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant tacrolimus: Given IV or PO sirolimus: Given PO Pharmacological Study: Correlative studies

   id

   FG000

   title

   Treatment (Clofarabine, Melphalan, Transplant)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         52

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         52

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

72 patients consented to the study. 52 of them became eligible and received the study treatment.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice